Ultragenyx announces approval of Dojolvi (UX007/triheptanoin) in Canada for the treatment of long-chain fatty acid oxidation disorders in adults and children

Ultragenyx

17 February 2021 - First approved treatment for adult and paediatric patients with long-chain fatty acid oxidation disorders in Canada.

Ultragenyx today announced that Health Canada has approved Dojolvi (triheptanoin) as a source of calories and fatty acids for the treatment of adult and paediatric patients with long-chain fatty acid oxidation disorders. 

Dojolvi is a highly purified, synthetic, 7 carbon fatty acid triglyceride specifically designed to provide medium-chain, odd-carbon fatty acids as an energy source and metabolite replacement for people with long-chain fatty acid oxidation disorders.

Read Ultragenyx press release 

Michael Wonder

Posted by:

Michael Wonder